...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical therapeutics >Monoclonal Antibodies in the Treatment of Metastatic Colorectal Cancer: A Review
【24h】

Monoclonal Antibodies in the Treatment of Metastatic Colorectal Cancer: A Review

机译：单克隆抗体治疗转移性结直肠癌的研究进展

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Two groups of agents targeting either the vascular endothelial growth factor (VEGF) receptor or the epidermal growth factor receptor (EGFR) have been added to the therapeutic arsenal against metastatic colorectal cancer (mCRC). Currently available agents in these groups are the anti-VEGF antibody bevacizumab and the anti-EGFR antibodies cetuximab and panitumumab.Objectives: This article reviews the results of prospective randomized clinical trials of anti-VEGF and anti-EGFR antibodies in mCRC, either as monothera-py, combined with chemotherapy, or combined with each other. Also reviewed are retrospective subset analyses of the effect of a KRAS mutation on the response to anti-EGFR antibodies.Methods: MEDLINE (2004-2009) was searched for randomized Phase II-III clinical trials of monoclonal antibodies in mCRC published in English. The search terms were colorectal neoplasms, bevacizumab, cetuximab, panitumumab, and KRAS mutation, alone or in combination. Information on the effect of KRAS mutation status on the response to anti-EGFR antibodies was drawn from retrospective subset analyses within the selected trials.
机译：背景：已将针对血管内皮生长因子（VEGF）受体或表皮生长因子受体（EGFR）的两组药物添加到抗转移性结直肠癌（mCRC）的治疗药库中。这些组中目前可用的药物是抗VEGF抗体贝伐单抗，抗EGFR抗体西妥昔单抗和帕尼单抗。 -py，与化学疗法结合，或彼此结合。还回顾了KRAS突变对抗EGFR抗体反应的影响的回顾性子集分析。方法：检索MEDLINE（2004-2009）在mCRC中以英语发表的随机II-III期单克隆抗体临床试验。搜索词是单独或组合使用的大肠肿瘤，贝伐单抗，西妥昔单抗，帕尼单抗和KRAS突变。有关KRAS突变状态对抗EGFR抗体反应的影响的信息来自所选试验中的回顾性亚组分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号